Estimating the lifetime cost of vaccination in 23 European Countries: a modeling study

All European countries have national immunization programs (NIPs) to protect gainst infectious diseases. We aimed to estimate the individual lifetime cost of vaccination in 23 European countries, assuming full compliance with NIP schedules. We used publicly available data to estimate the individual...

Full description

Saved in:
Bibliographic Details
Published in:Expert review of vaccines 2023-12, Vol.22 (1), p.148-160
Main Authors: Bencina, Goran, Bento-Abreu, André, Sabale, Ugne, Tsoumani, Eleana, Laigle, Valerie, Dauby, Nicolas, Ethgen, Olivier, Salomonsson, Stina
Format: Article
Language:English
Subjects:
Communicable Diseases
Cost-Benefit Analysis
Europe
health expenditures
Hospitalization
Humans
Immunization Programs
lifetime individual cost of vaccination
national immunization programs
Vaccination
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:All European countries have national immunization programs (NIPs) to protect gainst infectious diseases. We aimed to estimate the individual lifetime cost of vaccination in 23 European countries, assuming full compliance with NIP schedules. We used publicly available data to estimate the individual lifetime cost of vaccination with the vaccines that are currently recommended and funded in each country for healthy individuals and for individuals with underlying medical conditions. We included a scenario analysis for healthy individuals in which all currently recommended vaccines were universally funded, and compared the annual costs per person of vaccination to the annual per-capita costs of all-cause hospitalization and anti-infective medications. The individual lifetime cost of vaccination was €592-3,504 for healthy individuals (median: €1,663; 13-20 diseases), €744-9,081 for individuals with underlying conditions (median: €2,992; 13-21 diseases), and €1,225-4,832 (median: €2,565; 21-22 diseases) in the scenario analysis, with median values for vaccine acquisition of €1,203, €1,731, and €1,788, respectively. Our estimates show that the maximum potential cost of vaccination requires a relatively low level of investment assuming full compliance. These data could be useful for policymakers in future financial planning and evaluation of NIPs.
ISSN:1476-0584
1744-8395
DOI:10.1080/14760584.2023.2157266